First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects
Status:
Completed
Trial end date:
2017-01-03
Target enrollment:
Participant gender:
Summary
This study is a Phase 1, randomized, double-blind (Sponsor unblinded), placebo controlled,
dose escalation study to determine the safety, tolerability and pharmacokinetics (PK) profile
of GSK3389404 as single (Part 1) and multiple subcutaneous (SC) injections (Part 2) in
healthy subjects. This study represents the first administration of GSK3389404 in humans to
define the safety, tolerability and PK following single and multiple doses of GSK3389404 in
healthy subjects.